Anti-VEGFR-1 antibody: new biological drug with multiple therapeutic potentials
Therapeutic target: VEGFR-1, a membrane receptor for blood vessel growth factors (angiogenesis) of the VEGF family that has an important role in angiogenesis associated with cancer and other inflammatory diseases. This receptor is expressed in cells that line the blood vessels, in cancer cells and in some types of “bad” immune system cells that contribute to disease progression.
Selective inhibition of VEGFR-1 by the antibody D16F7 produced and patented by us: a) prevents the formation of blood vessels in the tumor and the generation of metastases, with less systemic toxicity than the most commonly used anti-angiogenic therapies; b) reduces the aggressiveness of the tumor, decreasing its ability to evade control by “bad” cells of the immune system; c) it could have a therapeutic potential also in other pathologies characterized by excessive angiogenesis and inflammation (e.g., pathologies of the retina and joints).
The monoclonal antibody D16F7 is the prototype of a potential biological drug that inhibits VEGFR-1 through a new mechanism of action that allows it to act at different levels in the treatment of very aggressive tumors (eg, melanoma and glioblastoma) and other diseases inflammatory.
- a) Inhibition of the formation of new blood vessels associated with: i) the tumor, to which they nourish and allow to migrate through the bloodstream to other sites and form metastases; ii) inflammatory diseases, such as a form of retinal disease that causes blindness in older people;
- b) inhibition of the recall of particular “bad” cells of the immune system which: i) help the tumor to develop and grow and escape the control of other “good” cells of the immune system which instead serve to counteract the aggressiveness of the tumor; ii) aggravate other diseases caused by inflammation;
- c) inhibition of the ability of cancer cells to migrate to other sites in our body.
- Main activity target against diseased tissue and not against normal non-diseased tissues;
- Reduced systemic toxicity;
- Possibility of being associated with other existing therapies to amplify their clinical response without increasing their toxicity;
- Thanks to the particular mechanism of action, it could be effective in low doses compared to other biological drugs currently in use;
- Lower cost of therapy.
- Treatment of tumor and inflammatory diseases whose severity is increased by the formation of new blood vessels;
- In the field of basic research, it represents a useful reagent to study the biological role of VEGFR-1 in angiogenesis, immune response, tumor proliferation and metastasis formation.